Moving molecules forward
Alumnus Toby Ferguson brings scientists together to transform discovery into breakthrough treatments
Oct. 7, 2026 –– Toby Ferguson’s biggest success was almost his biggest failure.
The neurologist and University of Florida College of Medicine alumnus led a team at Biogen to develop the first medicine for SOD1 ALS, a rare form of amyotrophic lateral sclerosis, or Lou Gehrig’s disease. Early data were promising, propelling the genetically-targeted therapy, called tofersen, from the research world into further clinical testing.
Ferguson, M.D.-Ph.D. ’01, was shocked when clinical evidence suggested the drug did not work.
Then, his team received data on a biomarker called neurofilament, an indicator of injury in the nervous system that spikes in people with ALS. These neurofilament levels decreased in ways never witnessed with any previously tested therapy.
“I remember going to people and saying, ‘Look, we should wait a little bit more to see if this is an important finding or not,’” he said. “What became apparent over time is that this drug worked and worked very well. Some people have gotten function back with this drug, which is the first time that’s ever been observed in ALS.”
He convinced his team to push past doubts surrounding the drug’s efficacy to decipher the biomarker changes. Ferguson engaged with scientists, clinicians, patients, advocacy groups and government regulators to advocate for the drug’s realization. It was a challenging period, he said, but one that awarded them a deeper understanding of the disease.
When regulatory agencies finally reviewed their data, the medication received accelerated approval.
Now, Ferguson is the senior vice president of Alnylam, a leading RNAi genetic therapeutics company. As head of neuroscience, he manages several teams working on programs that address chronic diseases such as Alzheimer’s and Huntington’s, providing them with ample resources and a strong direction.
“My day-to-day is helping these teams move each of their molecules forward,” he said.
‘A wide-open frontier’
Ferguson owes his professional growth to the many individuals who inspired him through his education and transition from academia to industry, beginning in a lab at the University of Florida.
As an undergraduate student, he sought out research opportunities since medicine had piqued his interest in high school. These courses taught him the basics of how to perform experiments and think scientifically, but most of all, they set him on a path of discovery, driven by a curiosity that still guides him.
He took an intensive six-week medical neuroscience course in his first year of medical school that set off sparks in his brain.
“I remember thinking this was the best thing ever,” Ferguson said. “It was just fantastic.”
Neurology then was a field focused on research and diagnosis since few treatment options were available. Wooed by the beauty, complexity and importance of the human nervous system, Ferguson saw the field as a “wide-open frontier.” He pursued UF’s combined M.D.-Ph.D. degree program, now the Medical Scientist Training Program, in hopes of adding to the intellectual canon of neuroscience.
“I wanted to try to discover something, and I wasn’t quite sure what that was,” he said. “But I wanted to understand how you generated new knowledge, how you contributed to science.”
The program opened up the world of human neuroanatomy to Ferguson. He was fascinated by the mechanisms in which neurons and cells communicated with each other. After the opening of UF’s Evelyn F. and William L. McKnight Brain Institute in 1998, a general enthusiasm regarding scientific exploration of the brain and potential therapies swept through campus.
Ferguson’s doctoral mentor, David Muir, Ph.D., was “translationally focused” on progressing research into the therapeutic realm. Some of Ferguson’s work in his lab was later licensed by a biotech company and approved as a therapy. These experiences ignited his interest in creating practical applications of medicine, which became a core takeaway from his time at UF.
While realizing his passion for neuroscience, Ferguson found another love in the lab. He met his wife, Tanya Ferguson, a fellow graduate student, when she struck up a conversation with him over slime molds. The pair of neuroscientists have been married since 1999.
“It’s great to see Dictyostelium expanding its scope beyond its evolutionary niche,” Ferguson recalled a professor joking when he heard about their relationship.
Fulfilling unmet needs in neuroscience
Ferguson graduated from UF enthralled by neurological and neuromuscular disease, moving on to complete his neurology residency and a neuromuscular fellowship at the University of Pennsylvania. While training there, the patients and professors he met inspired the gears of his mind to turn with the potential of making therapeutics.
“I thought the scientific possibility of new medicines in neurology was emerging,” Ferguson said. “And as I thought about setting up my own lab and having a clinical practice, I believed this was an area where I could potentially make a difference.”
To his own surprise, Ferguson took a “left turn” and entered the biotechnology industry. Motivated by fulfilling the unmet needs of neuroscience, his pivot presented itself as a logical step forward.
He took a job at Biogen after leaving his role as an assistant professor of neurology, holding positions of increasing responsibility until he was leading his own team of scientists.
Though he has worked as a physician, researcher and now leader in developing biopharmaceuticals, Ferguson believes his goals are impossible to reach alone. His focus is on bringing the right people together to “contribute their piece,” like neurons in a circuit. By sticking to this collaborative process, he hopes to change the world of medicine.
Another lesson Ferguson has gleaned over time is that failure is inevitable but can be as insightful as success.
“Most of the things I’ve worked on in my lab have failed,” he said. “When things fail, you think about it, you learn some lessons and you try to reapply those. Hopefully, each experiment you do tells you a bit. So next time, you’re a bit smarter, you do things a bit better.”
No matter the outcome, Ferguson allows the data to tell him where to go next. He advises young researchers to be honest in their interpretations and trust their gut, even in the face of disagreement.
At a public forum hosted after tofersen was approved, Ferguson heard dozens of ALS patients speak about the impact of the medication on their livelihood. One man who had lost his mother just two years after her SOD1 ALS diagnosis was able to live four years using tofersen and regain some walking ability.
“I know every day why I get up,” he said. “I get up so I can work to make medicines that change people’s lives.”